Mirabegrón Cinfamed (Mirabegron)

Mirabegron, the active ingredient in Mirabegrón Cinfamed, is a β3‑adrenergic receptor agonist presented as an oral dosage form for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency and urge incontinence in adults.

GNH USA supplies Mirabegrón Cinfamed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegrón is a β3‑adrenergic receptor agonist used in the management of lower urinary tract disorders. - Overactive bladder: increases bladder capacity and reduces the frequency of urgency episodes. - Urinary urgency: lessens the sudden, compelling need to void. - Urge urinary incontinence: decreases involuntary leakage associated with urgency.

Adverse reactions may occur with mirabegron therapy.

Common Side Effects: - Hypertension: elevated blood pressure observed in some patients. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient cranial pain. - Constipation: reduced bowel motility. - Dry mouth: decreased salivation. - Urinary retention: difficulty initiating or maintaining urine flow.

Serious or Rare Side Effects: - Severe hypertension: marked increase in blood pressure requiring medical attention. - Tachycardia: rapid heart rate that may be symptomatic. - Angioedema: swelling of face, lips, or airway. - Acute urinary retention leading to bladder overdistension. - Allergic reactions: rash, pruritus, or anaphylaxis. - QT interval prolongation: potential cardiac conduction abnormality.

Before initiating mirabegron, clinicians should consider several safety factors. - Monitor blood pressure: check baseline and periodic readings. - Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic function: caution in moderate to severe liver disease. - Review concomitant antihypertensives: risk of additive blood‑pressure effects. - Caution in narrow‑angle glaucoma: may exacerbate intra‑ocular pressure. - Store at room temperature: keep in the original container, protect from moisture.

Mirabegrón can interact with other medicines through metabolic pathways and pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise plasma concentrations. - Combined antimuscarinic therapy: heightened risk of urinary retention.

Moderate Interactions (Monitor Closely):\n- CYP2D6 substrates (e.g., metoprolol): may require dose adjustment. - CYP3A4 substrates (e.g., midazolam): monitor for enhanced effects. - Antihypertensive agents: possible additive hypotensive effect.